File Download

There are no files associated with this item.

Conference Paper: Bismuth Compounds as Novel Antagonists Against Toxicity of Cisplatin

TitleBismuth Compounds as Novel Antagonists Against Toxicity of Cisplatin
Authors
Issue Date2016
PublisherUniversity of Auckland.
Citation
8th Asian Biological Inorganic Chemistry Conference (AsBIC conference), Auckland, New Zealand, 4-9 December 2016. In Conference Handbook, p. 130 How to Cite?
AbstractCisplatin is one of the most effective anticancer drugs. However, it suffers severe side effects, in particular nephrotoxicity. Some metallo-compounds, such as zinc sulphate and Bi(NO3)3 were found to be able to reduce the toxicity of cisplatin. However they suffer from low in vivo efficacy and there lacks large-scale pre-clinical evaluation on their effectiveness. We designed and synthesized a series of bismuth compounds for reduction of side effects of cisplatin. Among them, BicitZ, Bi-L1 and Bi-L12 were screened out and exert excellent nephroprotective activity under both in vitro and in vivo conditions. We also found the pre-administration of Bi-L1, Bi-L12 and BicitZ exerts negligible effects on cisplatin’s anti-cancer activity in the tumor-engrafted mice. Several key proteins with altered expression levels in response to bismuth compounds and/or cisplatin treatment were identified and would be used for further function validation. Our work may offer an effective alternative of nephroprotective agent for alleviating the side effect of cisplatin treatment in human. We thank the Innovation Technology Commission of HKSAR (ITS/085/14) and the University of Hong Kong for financial support. References [1] Lloyd, K; Nat. Rev., 2007, 7, 573-584 [2] Wang, D; Lippard, SJ, Nat. Rev. Drug Discov., 2005, 4, 307-320 [3] Satoh, M., Aoki, Y., Tohyama, C. Cancer. Chemoth. Pharm.,1997, 40, 358
DescriptionPoster Session 2: Even Numbers: Metals in Medicine - no. 214
Persistent Identifierhttp://hdl.handle.net/10722/247757

 

DC FieldValueLanguage
dc.contributor.authorWang, R-
dc.contributor.authorChan, S-
dc.contributor.authorChan, GCF-
dc.contributor.authorLi, H-
dc.contributor.authorSun, H-
dc.date.accessioned2017-10-18T08:32:09Z-
dc.date.available2017-10-18T08:32:09Z-
dc.date.issued2016-
dc.identifier.citation8th Asian Biological Inorganic Chemistry Conference (AsBIC conference), Auckland, New Zealand, 4-9 December 2016. In Conference Handbook, p. 130-
dc.identifier.urihttp://hdl.handle.net/10722/247757-
dc.descriptionPoster Session 2: Even Numbers: Metals in Medicine - no. 214-
dc.description.abstractCisplatin is one of the most effective anticancer drugs. However, it suffers severe side effects, in particular nephrotoxicity. Some metallo-compounds, such as zinc sulphate and Bi(NO3)3 were found to be able to reduce the toxicity of cisplatin. However they suffer from low in vivo efficacy and there lacks large-scale pre-clinical evaluation on their effectiveness. We designed and synthesized a series of bismuth compounds for reduction of side effects of cisplatin. Among them, BicitZ, Bi-L1 and Bi-L12 were screened out and exert excellent nephroprotective activity under both in vitro and in vivo conditions. We also found the pre-administration of Bi-L1, Bi-L12 and BicitZ exerts negligible effects on cisplatin’s anti-cancer activity in the tumor-engrafted mice. Several key proteins with altered expression levels in response to bismuth compounds and/or cisplatin treatment were identified and would be used for further function validation. Our work may offer an effective alternative of nephroprotective agent for alleviating the side effect of cisplatin treatment in human. We thank the Innovation Technology Commission of HKSAR (ITS/085/14) and the University of Hong Kong for financial support. References [1] Lloyd, K; Nat. Rev., 2007, 7, 573-584 [2] Wang, D; Lippard, SJ, Nat. Rev. Drug Discov., 2005, 4, 307-320 [3] Satoh, M., Aoki, Y., Tohyama, C. Cancer. Chemoth. Pharm.,1997, 40, 358 -
dc.languageeng-
dc.publisherUniversity of Auckland. -
dc.relation.ispartof8th Asian Biological Inorganic Chemistry Conference, 2016-
dc.titleBismuth Compounds as Novel Antagonists Against Toxicity of Cisplatin-
dc.typeConference_Paper-
dc.identifier.emailChan, S: schan88@hkucc.hku.hk-
dc.identifier.emailChan, GCF: gcfchan@hku.hk-
dc.identifier.emailLi, H: hylichem@hku.hk-
dc.identifier.emailSun, H: hsun@hku.hk-
dc.identifier.authorityChan, GCF=rp00431-
dc.identifier.authoritySun, H=rp00777-
dc.identifier.hkuros281709-
dc.identifier.spage130-
dc.identifier.epage130-
dc.publisher.placeAuckland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats